enzh-TWfrdeitjaptrues

This is where we will be posting upcoming events of note.  Please return to this page as we intend to update on a regular basis.

Latest Bing Center News

Infection Prevention Strategies for Waldenstrom's Macroglobulinemia

Infection Prevention Strategies for Waldenstrom's Macroglobulinemia

This video webinar was presented by Dr. Andrew Branagan on September 15, 2021 as part of the IWMF's ongoing series of Ed Forum Workshops.

Read more..

When Should a Patient Seek Treatment for Waldenstrom Macroglobulinemia?

When Should a Patient Seek Treatment for Waldenstrom Macroglobulinemia?

Approximately 30% of Waldenstrom macroglobulinemia patients are advised to "watch and wait" at time of diagnosis. When should a patient seek treatment?

Read more..

Timely Updates in the Treatment of Waldenstrom's Macroglobulinemia

Timely Updates in the Treatment of Waldenstrom's Macroglobulinemia

As a follow-up to our recent announcement regarding the FDA approval of Zanabrutinib for the treatment of Waldenstrom's Macroglobulinemia (Sept 2, 2021), we are pleased to share this lecture, presented as a webinar on September 24, 2021 by Dr. Steven Treon.

Read more..

Newsweek Names Dana-Farber #3 in the World for Cancer

Newsweek Names Dana-Farber #3 in the World for Cancer

Dana-Farber has been named one of the world’s best cancer hospitals by Newsweek in its new World’s Best Specialized Hospitals 2022 rankings. Dana-Farber was ranked #3 globally. We are the only hospital in New England to be ranked in the top 15 for oncology.

Read more..

FDA Approves Zanubrutinib for the Treatment of Waldenströms Macroglobulinemia

FDA Approves Zanubrutinib for the Treatment of Waldenströms Macroglobulinemia

“The ASPEN trial provided compelling evidence that Brukinsa is a highly active BTK inhibitor in Waldenström’s macroglobulinemia, and compared to the first-generation BTK inhibitor, showed improved tolerability across a number of clinically important side effects. The approval of BRUKINSA provides an important new option for targeted therapy in Waldenström’s macroglobulinemia,” Steven Treon, MD, PhD, director of the Bing Center for Waldenström’s Macroglobulinemia Research at the Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School, said in a statement.

Read more..

LLS National Blood Cancer Conference, September 18, 2021

LLS National Blood Cancer Conference, September 18, 2021

This Blood Cancer Conference is one of many programs developed by The Leukemia & Lymphoma Society to meet the needs of patients, survivors, families and oncology professionals, the people who deal with blood cancer every day and the people who care for them. BCC attendees receive the most current information and access to local resources to help navigate and make informed decisions about their treatment and survivorship.

Read more..

18th International Myeloma Workshop, September 8-11, 2021

18th International Myeloma Workshop, September 8-11, 2021

The International Myeloma Workshop is the defining annual meeting in myeloma with a focus on both the basic, preclinical and the clinical aspects, including: Scientific Programs, Oral Presentations (on Basic Biology, Preclinical Trials and Clinical Studies), Consensus Panels, Poster Presentations.

Read more..

NCCN Guidelines Add Zanubrutinib as Preferred Therapy for Waldenström Macroglobulinemia

NCCN Guidelines Add Zanubrutinib as Preferred Therapy for Waldenström Macroglobulinemia

The NCCN Guidelines Version 1.2022 Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma (WM/LPL) were updated to include zanubrutinib as a preferred regimen for the primary therapy of WM/LPL along with bendamustine/rituximab, bortezomib/dexamethasone/rituximab, ibrutinib ± rituximab, and rituximab/cyclophosphamide/dexamethasone. Preferred interventions are based on superior efficacy, safety, and evidence.

Read more..

The 300 Project forges ahead with Bliss gift

The 300 Project forges ahead with Bliss gift

“We are looking at how cancer cells from patients who may not seem connected clinically may be utilizing the same networks through different mechanisms,” explains Zachary Hunter, PhD, one of the project’s leaders.

Read more..

A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies

A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies

This article reviews the pharmacology, clinical efficacy, safety, dosing, drug-drug interactions, and implications for advanced practitioners of BTK inhibitors in the treatment of B-cell malignancies.

Read more..